Mode
Text Size
Log in / Sign up
Phase 4 N=19 Randomized Triple-blind Supportive Care

A Pilot Study to Assess Effects of Self-Administered Nitrous Oxide (SANO) on Urodynamic Study (UDS) Parameters

Lower Urinary Tract Symptoms

Enrolled (actual)
19
Serious AEs
0.0%
Results posted
Mar 2026
Primary outcome: Primary: Bladder Capacity — 363; 402 milliliters

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Self-Administered Nitrous Oxide (Drug); Oxygen (Other)
Age
Adult, Older Adult · 21+ yrs
Sex
All
Sponsor
Beth Israel Deaconess Medical Center
Primary completion
Mar 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Bladder Capacity
363; 402
SECONDARY
Intra-Urodynamic Study (UDS) Pain
2; 0.7
SECONDARY
Intra-Urodynamic Study (UDS) Anxiety
2.0; 1
SECONDARY
Post Void Residual
132; 57
SECONDARY
Max Flow Rate
11; 11
SECONDARY
Detrusor Overactivity
4; 6
SECONDARY
Detrusor Pressure at Maximum Flow
45; 45

Summary

A urodynamic study (UDS) is a common procedure done to learn more about the cause of urinary symptoms. For some patients, UDS can be associated with anxiety or discomfort. Nitrous oxide (or laughing-gas) is a well-known sedative which is frequently used in dental offices and for pediatric procedures to reduce anxiety and pain. This study is being done to see if giving low-dose (20-50%) nitrous oxide at the time of UDS affects the measurements taken during the procedure, such as how much volume your bladder can hold, and pressures during urination. If the measurements are the same with and without self-administered nitrous oxide (SANO), it could be suggested that nitrous oxide may be a useful way of reducing patient anxiety and pain during UDS.

Eligibility Criteria

Inclusion Criteria

  • Scheduled for urodynamic study
  • Aged 21 to 85 years
  • Suitable for inflation of nitrous oxide/oxygen with willingness to undergo two urodynamic study runs during the procedure
  • Access to an email and computer

Exclusion Criteria

  • Perioral facial hair impeding good mask seal
  • Learning disabilities and/or inability to cognitively complete survey questions
  • Has any of the following medical conditions:
  • Inner ear, bariatric or eye surgery within the last 2 weeks,
  • Current emphysematous blebs,
  • Severe B-12 deficiency,
  • Bleomycin chemotherapy within the past year,
  • Heart attack within the past year,
  • Stroke within the past year,
  • Class III or higher heart failure
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05883332). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search